Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. Deborah W. Wilbur

Oncology | Hematology | Hematology Oncology

St Lukes Jones Regional Medical Center

1795 Hwy 64 E,

Anamosa, IA

Clinical Trials:Currently Recruiting for 3 Trials

Accepting New Patients

Offers Telehealth

Experienced in Primitive Neuroectodermal Tumor (PNET)

St Lukes Jones Regional Medical Center

1795 Hwy 64 E,

Anamosa, IA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Deborah Wilbur is an Oncologist and a Hematologist in Anamosa, Iowa. Dr. Wilbur is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Colorectal Cancer, Breast Cancer, Neuroendocrine Tumor, and Lung Adenocarcinoma. Dr. Wilbur is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 71 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Hematology

Hematology Oncology

Licenses

Internal Medicine in IA

Hospital Affiliations

Jones Regional Medical Center

Mercy Medical Center - Cedar Rapids

Regional Medical Center

St Lukes Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Managed Medicaid

OTHER MANAGED MEDICAID

Medica

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medical Associates

MEDICARE MAPD

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Northern Plains Alliance

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE PDP

TeamCare

OTHER COMMERCIAL

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

Wellmark

View 15 Less Insurance Carriers -

Locations

ST LUKES JONES REGIONAL MEDICAL CENTER
1795 Hwy 64 E, Anamosa, IA 52205

Call: 319-462-6131

Other Locations

MERCY MEDICAL CENTER
701 10th St Se, Cedar Rapids, IA 52403

Call: 319-398-6011

MERCY MEDICAL CENTER
709 W Main St, Manchester, IA 52057

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

69 Clinical Trials

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Enrollment Status: Recruiting

Publish Date: September 25, 2025

Intervention Type: Other

Study Phase: Not Applicable

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study

Enrollment Status: Recruiting

Publish Date: September 25, 2025

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

Enrollment Status: Recruiting

Publish Date: January 13, 2025

Intervention Type: Other, Biological, Drug

Study Drugs: Trastuzumab Emtansine, Tucatinib

Study Phase: Phase 3

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Enrollment Status: Active_not_recruiting

Publish Date: October 08, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Cabozantinib S-malate

Study Phase: Phase 3

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: October 01, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 30, 2025

Intervention Type: Radiation

Study Phase: Phase 3

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 2

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Trametinib

Study Phase: Phase 2

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride

Study Phase: Phase 2

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Lenalidomide

Study Phase: Phase 3

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Other, Radiation, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Enrollment Status: Active_not_recruiting

Publish Date: September 17, 2025

Intervention Type: Other, Drug

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study

Enrollment Status: Active_not_recruiting

Publish Date: September 10, 2025

Intervention Type: Procedure

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Behavioral

Study Phase: Phase 3

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer

Enrollment Status: Completed

Publish Date: September 05, 2025

Intervention Type: Procedure

Study Phase: Phase 3

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Enrollment Status: Active_not_recruiting

Publish Date: September 02, 2025

Intervention Type: Other, Drug, Radiation, Procedure

Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide

Study Phase: Phase 3

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Enrollment Status: Active_not_recruiting

Publish Date: August 14, 2025

Intervention Type: Drug

Study Drug: Sotorasib

Study Phase: Phase 2

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: August 05, 2025

Intervention Type: Radiation, Drug, Other

Study Drugs: Cisplatin, Triapine

Study Phase: Phase 3

The National Myelodysplastic Syndromes Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: July 02, 2025

Intervention Type: Other

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Completed

Publish Date: May 21, 2025

Intervention Type: Drug

Study Drug: Rucaparib

Study Phase: Phase 2

Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases

Enrollment Status: Completed

Publish Date: May 16, 2025

Intervention Type: Other, Drug

Study Drugs: Cisplatin, Veliparib

Study Phase: Phase 2

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Enrollment Status: Active_not_recruiting

Publish Date: May 09, 2025

Intervention Type: Drug, Other, Radiation

Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide

Study Phase: Phase 2/Phase 3

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)

Enrollment Status: Active_not_recruiting

Publish Date: May 07, 2025

Intervention Type: Drug, Other

Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 2/Phase 3

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Enrollment Status: Active_not_recruiting

Publish Date: April 18, 2025

Intervention Type: Procedure, Biological, Drug, Radiation

Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine

Study Phase: Phase 2

Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)

Enrollment Status: Active_not_recruiting

Publish Date: April 08, 2025

Intervention Type: Drug, Biological

Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide

Study Phase: Phase 2

Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Enrollment Status: Completed

Publish Date: April 06, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

Enrollment Status: Active_not_recruiting

Publish Date: April 03, 2025

Intervention Type: Other, Behavioral

Study Phase: Not Applicable

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Enrollment Status: Active_not_recruiting

Publish Date: March 30, 2025

Intervention Type: Drug

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 19, 2025

Intervention Type: Drug

Study Drugs: TAK-700, Bicalutamide

Study Phase: Phase 3

Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women With Dense Breasts

Enrollment Status: Active_not_recruiting

Publish Date: March 10, 2025

Intervention Type: Other, Diagnostic test

Study Phase: Not Applicable

Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent

Enrollment Status: Active_not_recruiting

Publish Date: February 17, 2025

Intervention Type: Other

Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias

Enrollment Status: Completed

Publish Date: January 28, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Phase: Phase 3

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: a Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 17, 2025

Intervention Type: Other, Drug

Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine

Study Phase: Phase 2/Phase 3

Evaluation of Mammographic Breast Density Effect of Aspirin: a Companion Study to Alliance Study A011502

Enrollment Status: Terminated

Publish Date: January 16, 2025

Intervention Type: Procedure

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Other, Dietary supplement, Drug

Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan

Study Phase: Phase 3

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Radiation, Procedure

Study Phase: Phase 3

View 47 Less Clinical Trials

1 Total Publications

Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer.

Journal: Journal of geriatric oncology

Published: September 16, 2020

Similar Doctors

Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Mark W. Karwal

Hematology Oncology | Oncology | Hematology

Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Mark W. Karwal

Hematology Oncology | Oncology | Hematology

State University Of Iowa

200 Hawkins Dr,

Iowa City, IA

(33.9 miles away)

319-356-1616

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Mark Karwal is a Hematologist Oncology specialist and an Oncologist in Iowa City, Iowa. Dr. Karwal is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Angiosarcoma, Breast Cancer, Inflammatory Breast Cancer, and Fibrolamellar Carcinoma. Dr. Karwal is currently accepting new patients.

Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Margaret M. Byrne

Oncology | Hematology | Hematology Oncology

Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Margaret M. Byrne

Oncology | Hematology | Hematology Oncology

State University Of Iowa

200 Hawkins Dr,

Iowa City, IA

(33.9 miles away)

319-356-1616

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Margaret Byrne is an Oncologist and a Hematologist in Iowa City, Iowa. Dr. Byrne is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Primitive Neuroectodermal Tumor (PNET), and Posterior Fossa Tumor. Dr. Byrne is currently accepting new patients.

Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Susannah P. Friemel

Hematology Oncology | Hematology | Oncology

Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Susannah P. Friemel

Hematology Oncology | Hematology | Oncology

Iowa Cancer Specialists

1750 E 53rd St,

Davenport, IA

(52.0 miles away)

563-345-4325

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Susannah Friemel is a Hematologist Oncology specialist and a Hematologist in Davenport, Iowa. Dr. Friemel and is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Anemia, and Familial Colorectal Cancer. Dr. Friemel is currently accepting new patients.

VIEW MORE PRIMITIVE NEUROECTODERMAL TUMOR (PNET) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilbur's expertise for a condition

ConditionClose